## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingt	on, D.C.	20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Harper Sean E				2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]									Check a	tionship of Reportin all applicable) Director Officer (give title		100	o Issuer % Owner ner (specify		
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 03/25/2016										X	below) EVP, Research		bel	ow)	
(Street) THOUSA OAKS	C.		)1320-179	99	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						. Individine)	-7						
(City)	(51		Zip)		<u> </u>									<u> </u>					
						_			_	, Dis	posed o								
Date			Date	te Ex onth/Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)					Securities Acquired (A) sposed Of (D) (Instr. 3, 4			id 5)   :	Securities Beneficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect	
									Code	v	Amount	(	(A) or (D)	Price	- 1	Transaction(s) (Instr. 3 and 4)			(1130.4)
Common Stock 03/			03/25/	5/2016				F		23,785		D	\$149	9.24	4 65,782 <sup>(1)(2)</sup>		D		
		Та									osed of, onvertib					ned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (I 8)		5. Nui of Derivi Secui Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired osed . 3, 4	6. Date I Expiration (Month/II	on Da		Amo Sec Und Deri	An	ı	8. Prio Deriva Secur (Instr.	ative rity	9. Number of derivative Securities Beneficially Beneficially Owned Following Reported Transactions (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)

## **Explanation of Responses:**

- 1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,943 RSUs which vest on 4/27/2016; 2,543 RSUs which vest on 1/28/2017; 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1,340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 2. These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

/s/ Sean E. Harper 03/28/2016

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.